Toll Free: 1-888-928-9744

Lytix Biopharma AS - Product Pipeline Review - 2015

Published: Jul, 2015 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lytix Biopharma AS - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Lytix Biopharma AS - Product Pipeline Review - 2015', provides an overview of the Lytix Biopharma AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lytix Biopharma AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lytix Biopharma AS including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lytix Biopharma AS's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Lytix Biopharma AS's pipeline products

Reasons to buy

- Evaluate Lytix Biopharma AS's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lytix Biopharma AS in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lytix Biopharma AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lytix Biopharma AS and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lytix Biopharma AS
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Lytix Biopharma AS and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Lytix Biopharma AS Snapshot 5 Lytix Biopharma AS Overview 5 Key Information 5 Key Facts 5 Lytix Biopharma AS - Research and Development Overview 6 Key Therapeutic Areas 6 Lytix Biopharma AS - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Lytix Biopharma AS - Pipeline Products Glance 12 Lytix Biopharma AS - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Lytix Biopharma AS - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Lytix Biopharma AS - Drug Profiles 16 LTX-109 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 LTX-315 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Drugs for Oncology 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Drugs to Inhibit CTLA4 for Oncology + LTX-315 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Drug to Target Kinase for Undisclosed Indication 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecules for Oncology 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Lytix Biopharma AS - Pipeline Analysis 24 Lytix Biopharma AS - Pipeline Products by Target 24 Lytix Biopharma AS - Pipeline Products by Route of Administration 25 Lytix Biopharma AS - Pipeline Products by Molecule Type 26 Lytix Biopharma AS - Pipeline Products by Mechanism of Action 27 Lytix Biopharma AS - Recent Pipeline Updates 28 Lytix Biopharma AS - Dormant Projects 30 Lytix Biopharma AS - Locations And Subsidiaries 31 Head Office 31 Other Locations & Subsidiaries 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
Lytix Biopharma AS, Key Information 5 Lytix Biopharma AS, Key Facts 5 Lytix Biopharma AS - Pipeline by Indication, 2015 7 Lytix Biopharma AS - Pipeline by Stage of Development, 2015 9 Lytix Biopharma AS - Monotherapy Products in Pipeline, 2015 10 Lytix Biopharma AS - Combination Treatment Modalities in Pipeline, 2015 11 Lytix Biopharma AS - Phase II, 2015 12 Lytix Biopharma AS - Phase I, 2015 13 Lytix Biopharma AS - Preclinical, 2015 14 Lytix Biopharma AS - Discovery, 2015 15 Lytix Biopharma AS - Pipeline by Target, 2015 24 Lytix Biopharma AS - Pipeline by Route of Administration, 2015 25 Lytix Biopharma AS - Pipeline by Molecule Type, 2015 26 Lytix Biopharma AS - Pipeline Products by Mechanism of Action, 2015 27 Lytix Biopharma AS - Recent Pipeline Updates, 2015 28 Lytix Biopharma AS - Dormant Developmental Projects,2015 30 Lytix Biopharma AS, Other Locations 31



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify